Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
Primary Purpose
Hyperhidrosis
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Dose 1 of glycopyrrolate, 2.0% QD
Dose 2 of glycopyrrolate, 3.0% QD
Dose 1 of glycopyrronium, 2.5% QD
Dose 2 of glycopyrronium, 3.75% QD
Vehicle
Sponsored by
About this trial
This is an interventional treatment trial for Hyperhidrosis
Eligibility Criteria
Inclusion Criteria:
- Male or female, 18 years of age or older.
- Primary, axillary hyperhidrosis of at least 6 months duration.
- Hyperhidrosis Disease Severity Score (HDSS) of 3 or 4 at baseline.
- For each axilla, a baseline gravimetric measurement of sweat production of at least 50 mg over 5 minutes, while at rest, at room temperature.
- Male or non-pregnant, non-lactating females.
Exclusion Criteria:
- Current pregnancy or lactation.
- Prior surgical procedure for hyperhidrosis.
- Any prior axillary treatment with an anti-hyperhidrosis medical device
- Any prior treatment with an investigational drug within 4 weeks prior to Baseline/Day 1 or within 5 elimination half lives of the active agent, whichever is longer or 6 weeks if the elimination half life is not known. Experimental devices are excluded without the approval of the Medical Monitor.
- Prior treatment with botulinum toxin (e.g., Botox®) for axillary hyperhidrosis within 1 year of Baseline/Day 1.
- Subjects with clinically significant abnormalities in laboratory values.
- Subjects with a positive Hepatitis or HIV.Hepatitis B surface antibody positive is allowed only if the subject has a history of having received Hepatitis B vaccination and there are no clinically significant abnormalities in screening liver function tests.
- Treatment with cholinergic, serotonergic antagonists, and dopamine partial agonists thought to relieve antidepressant-induced hyperhidrosis, within one month prior to Baseline/Day 1.
- Treatment with psychotherapeutic medications for less than 4 months prior to Baseline/Day 1.
- Treatment with topical or systemic anticholinergics, adrenergic agonists (clonidine), or beta-blockers within 4 weeks of the baseline visit
- Prior treatment with axillary iontophoresis within 4 weeks of Baseline/Day 1.
- Any previous IV or oral treatment with the study drug.
- Prior treatment with the topical study drug in a previous trial.
- Axillary use of nonprescription or prescription antiperspirants within 2 weeks of study enrollment.
- Presence of a condition, within 10 years of enrollment, that may cause secondary hyperhidrosis
- Menopausal women who have had symptoms of menopause such as sweating or flushing within 3 years of the study may not be enrolled.
- Known history of Sjögren's syndrome or Sicca syndrome.
- History of glaucoma, inflammatory bowel disease, toxic megacolon, or febrile illness.
- Men with a history of urinary retention requiring catheterization due to prostatic hypertrophy or severe obstructive symptoms of prostatic hypertrophy.
- Abnormal findings on screening ECG deemed clinically significant by the Investigator.
- History or presence of ventricular arrhythmias, atrial fibrillation, atrial flutter. History of other supraventricular tachycardia
Sites / Locations
- California Dermatology & Clinical Research Institute
- Center For Dermatology Clinical Research
- Olympian Clinical Research
- Kenneth R. Beer MD
- Shideler Clinical Research Center
- Saint Louis University Dermatology
- Haber Dermatology and Cosmetic Surgery
- Rivergate Dermatology Clinical Research Center, PLLC
- DermResearch, Inc
- Dermatology Research Center, Inc.
- Virginia Clinical Research, Inc.
- Dermatology Associates
- Women's Clinical Research Center
- Premier Clinical Research
- Innovaderm Research Inc.
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm Type
Experimental
Experimental
Active Comparator
Active Comparator
Placebo Comparator
Arm Label
Dose 1 of glycopyrrolate, 2.0% QD
Dose 2 of glycopyrrolate, 3.0% QD
Dose 1 of glycopyrronium, 2.5% QD
Dose 2 of glycopyrronium, 3.75% QD
Vehicle
Arm Description
glycopyrrolate Topical Wipes
glycopyrrolate Topical Wipes
glycopyrronium Topical Wipes
glycopyrronium Topical Wipes
Vehicle Topical Wipes
Outcomes
Primary Outcome Measures
Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4
HDSS is a disease specific diagnostic tool that provides a qualitative measure of the severity of the subjects' condition based on how it affects daily activities.
1 (Best), 2, 3, 4 (Worst)
Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 4
Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 6
Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 4
Subjects are acclimated to the environment for 30 minutes. Dry gauze is weighed. The dry gauze is then applied to the subject's axilla with the arm down by the subject's side or on their lap during the 5-minute period of sweat production. The gauze with the sweat is then weighed. The difference between the Weight of the gauze with sweat and the dry gauze is the gravimetric sweat measurement in mg/5min.
Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 6
Secondary Outcome Measures
Percentage of Subjects Who Had at Least 50% Reduction in Gravimetrically Measured Sweat Production From Baseline at Week 4
Percentage of Subjects Who Had at Least 50% Reduction in Gravimetrically Measured Sweat Production From Baseline at Week 6
Full Information
NCT ID
NCT02129660
First Posted
April 30, 2014
Last Updated
August 23, 2021
Sponsor
Journey Medical Corporation
1. Study Identification
Unique Protocol Identification Number
NCT02129660
Brief Title
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
Official Title
A Phase 2, Randomized, Double-Blind Vehicle-Controlled Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
April 2014 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
January 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Journey Medical Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the study is to assess the safety of 2 doses of glycopyrrolate compared to 2 doses of glycopyrronium and vehicle (5 treatment arms) for the treatment of axillary hyperhidrosis when applied once daily for 4 weeks followed by a 2-week post-dose period.
Detailed Description
This is a randomized, double-blind, vehicle controlled, parallel group, comparator study designed to assess the safety, efficacy and pharmacokinetics of two doses of glycopyrrolate compared to two doses of glycopyrronium compared to vehicle, 5 treatment arms.
Efficacy will be assessed through gravimetric assessment of sweat production using Patient Reported Outcome and the Hyperhidrosis Disease Severity Score (HDSS).
Safety will be assessed through adverse events, local skin responses, serum chemistry and hematology laboratory testing, ECGs, physical examination and vital signs.
PK blood samples will be taken study subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperhidrosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
105 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dose 1 of glycopyrrolate, 2.0% QD
Arm Type
Experimental
Arm Description
glycopyrrolate Topical Wipes
Arm Title
Dose 2 of glycopyrrolate, 3.0% QD
Arm Type
Experimental
Arm Description
glycopyrrolate Topical Wipes
Arm Title
Dose 1 of glycopyrronium, 2.5% QD
Arm Type
Active Comparator
Arm Description
glycopyrronium Topical Wipes
Arm Title
Dose 2 of glycopyrronium, 3.75% QD
Arm Type
Active Comparator
Arm Description
glycopyrronium Topical Wipes
Arm Title
Vehicle
Arm Type
Placebo Comparator
Arm Description
Vehicle Topical Wipes
Intervention Type
Drug
Intervention Name(s)
Dose 1 of glycopyrrolate, 2.0% QD
Other Intervention Name(s)
DRM04B
Intervention Description
Dose 1 of glycopyrrolate Topical Wipes
Intervention Type
Drug
Intervention Name(s)
Dose 2 of glycopyrrolate, 3.0% QD
Other Intervention Name(s)
DRM04B
Intervention Description
Dose 2 of glycopyrrolate Topical Wipes
Intervention Type
Drug
Intervention Name(s)
Dose 1 of glycopyrronium, 2.5% QD
Other Intervention Name(s)
DRM04
Intervention Description
Dose 1 of glycopyrronium Topical Wipes
Intervention Type
Drug
Intervention Name(s)
Dose 2 of glycopyrronium, 3.75% QD
Other Intervention Name(s)
DRM04
Intervention Description
Dose 2 of glycopyrronium Topical Wipes
Intervention Type
Other
Intervention Name(s)
Vehicle
Intervention Description
Vehicle Topical Wipes
Primary Outcome Measure Information:
Title
Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4
Description
HDSS is a disease specific diagnostic tool that provides a qualitative measure of the severity of the subjects' condition based on how it affects daily activities.
1 (Best), 2, 3, 4 (Worst)
Time Frame
Baseline - Week 4/ET
Title
Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 4
Time Frame
Baseline - Week 4
Title
Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 6
Time Frame
Baseline - Week 6
Title
Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 4
Description
Subjects are acclimated to the environment for 30 minutes. Dry gauze is weighed. The dry gauze is then applied to the subject's axilla with the arm down by the subject's side or on their lap during the 5-minute period of sweat production. The gauze with the sweat is then weighed. The difference between the Weight of the gauze with sweat and the dry gauze is the gravimetric sweat measurement in mg/5min.
Time Frame
Baseline - Week 4
Title
Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 6
Time Frame
Baseline - Week 6
Secondary Outcome Measure Information:
Title
Percentage of Subjects Who Had at Least 50% Reduction in Gravimetrically Measured Sweat Production From Baseline at Week 4
Time Frame
Baseline - Week 4
Title
Percentage of Subjects Who Had at Least 50% Reduction in Gravimetrically Measured Sweat Production From Baseline at Week 6
Time Frame
Baseline - Week 6
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female, 18 years of age or older.
Primary, axillary hyperhidrosis of at least 6 months duration.
Hyperhidrosis Disease Severity Score (HDSS) of 3 or 4 at baseline.
For each axilla, a baseline gravimetric measurement of sweat production of at least 50 mg over 5 minutes, while at rest, at room temperature.
Male or non-pregnant, non-lactating females.
Exclusion Criteria:
Current pregnancy or lactation.
Prior surgical procedure for hyperhidrosis.
Any prior axillary treatment with an anti-hyperhidrosis medical device
Any prior treatment with an investigational drug within 4 weeks prior to Baseline/Day 1 or within 5 elimination half lives of the active agent, whichever is longer or 6 weeks if the elimination half life is not known. Experimental devices are excluded without the approval of the Medical Monitor.
Prior treatment with botulinum toxin (e.g., Botox®) for axillary hyperhidrosis within 1 year of Baseline/Day 1.
Subjects with clinically significant abnormalities in laboratory values.
Subjects with a positive Hepatitis or HIV.Hepatitis B surface antibody positive is allowed only if the subject has a history of having received Hepatitis B vaccination and there are no clinically significant abnormalities in screening liver function tests.
Treatment with cholinergic, serotonergic antagonists, and dopamine partial agonists thought to relieve antidepressant-induced hyperhidrosis, within one month prior to Baseline/Day 1.
Treatment with psychotherapeutic medications for less than 4 months prior to Baseline/Day 1.
Treatment with topical or systemic anticholinergics, adrenergic agonists (clonidine), or beta-blockers within 4 weeks of the baseline visit
Prior treatment with axillary iontophoresis within 4 weeks of Baseline/Day 1.
Any previous IV or oral treatment with the study drug.
Prior treatment with the topical study drug in a previous trial.
Axillary use of nonprescription or prescription antiperspirants within 2 weeks of study enrollment.
Presence of a condition, within 10 years of enrollment, that may cause secondary hyperhidrosis
Menopausal women who have had symptoms of menopause such as sweating or flushing within 3 years of the study may not be enrolled.
Known history of Sjögren's syndrome or Sicca syndrome.
History of glaucoma, inflammatory bowel disease, toxic megacolon, or febrile illness.
Men with a history of urinary retention requiring catheterization due to prostatic hypertrophy or severe obstructive symptoms of prostatic hypertrophy.
Abnormal findings on screening ECG deemed clinically significant by the Investigator.
History or presence of ventricular arrhythmias, atrial fibrillation, atrial flutter. History of other supraventricular tachycardia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lynne M. Deans, MT
Organizational Affiliation
Dermira, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
California Dermatology & Clinical Research Institute
City
Encinitas
State/Province
California
ZIP/Postal Code
92024
Country
United States
Facility Name
Center For Dermatology Clinical Research
City
Fremont
State/Province
California
ZIP/Postal Code
94538
Country
United States
Facility Name
Olympian Clinical Research
City
Tampa
State/Province
Florida
ZIP/Postal Code
33609
Country
United States
Facility Name
Kenneth R. Beer MD
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33401
Country
United States
Facility Name
Shideler Clinical Research Center
City
Carmel
State/Province
Indiana
ZIP/Postal Code
46032
Country
United States
Facility Name
Saint Louis University Dermatology
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63122
Country
United States
Facility Name
Haber Dermatology and Cosmetic Surgery
City
Beachwood
State/Province
Ohio
ZIP/Postal Code
44122
Country
United States
Facility Name
Rivergate Dermatology Clinical Research Center, PLLC
City
Goodlettsville
State/Province
Tennessee
ZIP/Postal Code
37072
Country
United States
Facility Name
DermResearch, Inc
City
Austin
State/Province
Texas
ZIP/Postal Code
78759
Country
United States
Facility Name
Dermatology Research Center, Inc.
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84117
Country
United States
Facility Name
Virginia Clinical Research, Inc.
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23507
Country
United States
Facility Name
Dermatology Associates
City
Seattle
State/Province
Washington
ZIP/Postal Code
98101
Country
United States
Facility Name
Women's Clinical Research Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98105
Country
United States
Facility Name
Premier Clinical Research
City
Spokane
State/Province
Washington
ZIP/Postal Code
99204
Country
United States
Facility Name
Innovaderm Research Inc.
City
Montreal
ZIP/Postal Code
H2K 4L5
Country
Canada
12. IPD Sharing Statement
Citations:
PubMed Identifier
33433785
Citation
Pariser DM, Lain EL, Mamelok RD, Drew J, Mould DR. Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis. Clin Pharmacokinet. 2021 May;60(5):665-676. doi: 10.1007/s40262-020-00975-y. Epub 2021 Jan 12.
Results Reference
derived
Learn more about this trial
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
We'll reach out to this number within 24 hrs